Companies
Mammoth Biosciences
CRISPR diagnostics pioneer (Jennifer Doudna co-founder) — SHERLOCK-based DETECTR platform for rapid point-of-care pathogen detection with sub-attomolar sensitivity.
- Country
- United States
- Revenue
- ~$20M
- Employees
- ~100 emp
ISO 13485
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $375M raised to date | mammoth.bio |
| Regulatory approval | FDA Emergency Use Authorization for DETECTR BOOST SARS-CoV-2 Reagent Kit received in 2022 | businesswire.com |
| Production site | St. Louis, Missouri (manufacturing partner facility) | sigmaaldrich.com |
| Production site | Abu Dhabi (planned advanced therapy manufacturing facility) | drupal.prod.genomeweb.com · m42.ae · pharmamanufacturing.com |
| Capacity | High-throughput system capacity of 1,500 tests in an 8-hour shift medium confidence | sigmaaldrich.com |
| Certification | Tests performed in high complexity CLIA laboratories medium confidence | businesswire.com |
Independent sources: businesswire.com · drupal.prod.genomeweb.com · m42.ae · pharmamanufacturing.com · sigmaaldrich.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CRISPR diagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.